SequelSEC

Telomir Pharmaceuticals, Inc. TELO

Pharmaceutical Preparations · CIK 0001971532 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$18.10MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.53Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity3.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio5.14x61th

Telomir Pharmaceuticals, Inc. (TELO) reported net income of -$10.41M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Telomir Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Telomir Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
RevenueUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailableUnavailableUnavailable
Net income-$10.41M-$16.53M-$13.07M-$854.15K
Research & development$2.44M$2.24M$1.57M$833.21K
Weighted-average diluted sharesshares 31.65Mshares 29.54Mshares 27.30Mshares 26.83M
Pretax incomeUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.33$-0.56$0.48$-0.03
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$8.10M$9.64M$600.19K$20.94K
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Telomir Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalentsUnavailable$1.27MUnavailableUnavailable
Total assets$7.34M$1.32M$4.77M$48.73K
Current assets$7.34M$1.32M$435.22K$48.73K
Total liabilities$1.43M$680.97K$1.34M$986.01K
Current liabilities$1.43M$680.97K$1.34M$986.01K
Total equity incl. NCI$5.91M$643.04K$3.44M-$937.28K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailable

Cash flow

Telomir Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$3.69M-$5.07M-$3.86M-$468.66K
Capital expendituresUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailable
Financing cash flow$9.71M$6.34M$3.86M$470.08K
Net change in cash$6.02M$1.26M-$188$1.42K
Stock-based compensation$5.29M$6.87MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

Telomir Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio5.14x1.94x0.33x0.05x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TELO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.